Immunochemistry is the branch of science that uses antibodies to detect and measure specific molecules in biological samples. It underpins a huge range of medical tests, from pregnancy tests to cancer diagnostics, and relies on one core principle: antibodies bind to their targets with remarkable precision, and that binding event can be made visible or measurable.
How Antibodies Find Their Targets
Every immunochemistry technique starts with the same biological event: an antibody locks onto a specific molecule called an antigen. This isn’t a single strong chemical bond like the ones holding molecules together internally. Instead, it’s a combination of several weaker forces working together. Van der Waals forces, the weakest of these, attract molecules at extremely close range and fade rapidly with distance. Hydrogen bonds form between oppositely charged atoms and release energy as they connect. Hydrophobic interactions push water-avoiding parts of molecules together. None of these forces alone would hold an antibody to its target, but collectively they create a strong, specific grip.
Two terms describe how well this grip works. Affinity refers to how tightly a single binding site on an antibody attaches to its target. Avidity describes the combined strength when an antibody uses both of its binding sites at once. When both sites engage, the overall binding strength can increase by roughly a thousandfold. This is why antibody design matters so much in immunochemistry: small differences in binding strength translate into big differences in test sensitivity.
Monoclonal vs. Polyclonal Antibodies
The antibodies used in immunochemistry come in two main varieties, and each has trade-offs. Polyclonal antibodies are harvested from immunized animals and contain a complex mix of antibody molecules, each targeting slightly different parts of the same antigen. This diversity can be useful, but it also means some molecules in the mix may bind to unintended targets. Every batch is unique to the animal that produced it, performance can vary between lots, and once a batch runs out, it can’t be reproduced.
Monoclonal antibodies come from purified cell lines derived from a single immune cell. Each lot contains identical antibody molecules targeting the same precise spot on an antigen. They’re renewable as long as the cell line is maintained, and they perform consistently batch after batch. For these reasons, many laboratories have shifted toward monoclonal antibodies when standardized, reproducible results matter most.
ELISA: The Workhorse Technique
The enzyme-linked immunosorbent assay, or ELISA, is the most widely used immunochemistry method. It works by attaching antibodies or antigens to the surface of small wells in a plastic plate, then using enzyme-labeled antibodies to produce a color change that can be measured. There are several formats, each suited to different situations.
- Direct ELISA: The target antigen is stuck to the plate and detected by a single labeled antibody. It’s straightforward and commonly used to screen antibodies against a known antigen.
- Indirect ELISA: The antigen is coated onto the plate, then a primary antibody binds to it, followed by a labeled secondary antibody that amplifies the signal. This format is frequently used to measure antibody levels in blood samples, such as checking whether someone has mounted an immune response to an infection.
- Sandwich ELISA: Instead of coating the plate with antigen, a “capture” antibody is attached first. The sample antigen gets trapped between this capture antibody and a second labeled “detection” antibody. This makes it ideal for complex samples like tissue extracts where the target molecule is mixed in with many others.
- Competitive ELISA: Sample antigen competes with a known amount of antigen for binding to a limited supply of antibody. The more target molecule present in the sample, the less antibody binds to the plate, producing a weaker signal. This format works well for small molecules that only have one binding site and can’t accommodate two antibodies at once.
A standard ELISA takes about 180 minutes from start to result. It remains popular because it’s relatively inexpensive, doesn’t require specialized equipment, and can be run in large batches.
Chemiluminescence: Faster and More Sensitive
Many modern clinical labs have moved to chemiluminescence immunoassays, or CLIA, which replace the color-producing enzymes used in ELISA with molecules that emit light. This shift brings two practical advantages. Results come back in roughly 30 minutes compared to three hours for ELISA, and the technique is largely automated, reducing hands-on labor. At very low concentrations (below 1 nanogram per milliliter), CLIA outperforms ELISA in detecting trace amounts of a target molecule, though the two perform comparably at higher concentrations. This extra sensitivity matters when detecting biomarkers that circulate at tiny levels in the blood.
Immunohistochemistry: Seeing Proteins in Tissue
Immunohistochemistry, or IHC, applies immunochemistry principles directly to thin slices of tissue, typically biopsy samples. A primary antibody is applied to the tissue to bind a protein of interest. Then a labeled secondary antibody attaches to the first one, amplifying the signal. The label is usually an enzyme like horseradish peroxidase, which reacts with a chemical substrate to deposit a visible brown or red stain at the exact location of the target protein.
This technique is essential in cancer diagnosis. Pathologists use IHC to determine which proteins a tumor is expressing, which helps classify the type of cancer and guide treatment decisions. For example, breast cancer biopsies are routinely stained for hormone receptors and growth factor receptors that determine whether certain targeted therapies will be effective. The indirect method, where the secondary antibody carries the label, is preferred because it amplifies the signal and allows the same labeled secondary antibody to be paired with many different primary antibodies.
What Immunochemistry Detects in Clinical Practice
The range of molecules detected through immunochemistry is enormous. Cardiac troponin, a protein released when heart muscle is damaged, is routinely measured using immunoassays to diagnose heart attacks. The test is sensitive enough to detect subclinical heart damage, including injury caused by certain cancer treatments. Pregnancy tests detect human chorionic gonadotropin (HCG) in urine using a simple lateral-flow immunoassay, which is essentially a miniaturized, one-step version of the sandwich ELISA format.
Infectious disease testing relies heavily on these methods. Antibody levels against viruses, bacteria, and parasites are measured to determine whether someone has been exposed or vaccinated. Hormone levels, allergy markers, and drug concentrations in the blood are all quantified using immunochemistry platforms. Hospitals also use immunoassays to monitor levels of certain medications that have a narrow therapeutic range, ensuring doses stay effective without becoming toxic.
Multiplex Testing: Many Targets at Once
Traditional immunoassays measure one molecule per test. Newer multiplex platforms can detect up to 100 different targets in a single sample well. One widely used approach involves color-coded microscopic beads, each coated with a different capture antibody. The beads flow past lasers in a stream: one laser reads the bead’s color code to identify which target it’s measuring, while a second laser measures the fluorescent signal indicating how much of that target is present. This technology dramatically increases the information gained from a small sample volume and reduces both time and cost compared to running dozens of individual tests.
Another approach uses carbon electrode surfaces in microwell plates. Detection antibodies carry labels that emit light when electrically stimulated, eliminating the need for repeated washing steps and simplifying the procedure while maintaining sensitivity comparable to bead-based methods.
A Brief Origin Story
The field’s modern era began in 1959, when Solomon Berson and Rosalyn Yalow described the first immunoassay, a radioimmunoassay that used radioactive labels to measure insulin in blood. The technique was revolutionary because it could quantify hormones at concentrations far below what any chemical test could detect. Yalow received the Nobel Prize in Medicine in 1977 for this work. Since then, radioactive labels have been largely replaced by enzymes, fluorescent molecules, and chemiluminescent compounds, but the core principle remains unchanged: harness the specificity of antibody-antigen binding and attach a detectable signal to it.